A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: The prognostic role of blood monocyte and lymphocyte counts is absent

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Procházka, Vít ^a   Pytlík, Robert ^b   Janíková, Andrea ^c   Belada, David ^d   Šálek, David ^c   Papajík, Tomáš ^a   Campr, Vít ^b   Fürst, Tomáš ^a   Furstova, Jana ^a   Trněný, Marek ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ABSOLUTE LYMPHOCYTE COUNT; ABSOLUTE MONOCYTE COUNT; ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LYMPHOCYTE TO MONOCYTE RATIO; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL PREDICTION; VALIDATION STUDY; VERY ELDERLY; LYMPHOCYTE; LYMPHOMA, LARGE B-CELL, DIFFUSE; METHODOLOGY; MIDDLE AGED; MONOCYTE; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; SURVIVAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MONOCYTES; PREDNISONE; PROGNOSIS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 84904803452     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102594     Document Type: Article

References (26)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, et al. (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 107: 265-276. (Pubitemid 43053551)
2. Peyrade F, Gastaud L, Ré D, Pacquelet-Cheli S, Thyss A (2012) Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol. 13: 344-352.
3. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, et al. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 116: 2040-2045.
4. Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile J-F, et al. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 12: 460-468.
5. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, et al. (2011) The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica. 96: 1888-1890.
6. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A Predictive Model for Aggressive Non-Hodgkin's Lymphoma. N Engl J Med. 329: 987-994.
7. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, et al. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with RCHOP. Blood. 109: 1857-1861. (Pubitemid 46348180)
8. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, et al. (2010) Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+ B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology. 28: 2373-2380.
9. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, et al. (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Lancet Oncol. 9: 105-116.
10. Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, et al. (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). British Journal of Haematology. 151: 143-151.
11. Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, et al. (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell- lymphoma. Leuk Lymphoma. 49: 1745-1751.
12. Talaulikar D, Choudhury A, Shadbolt B, Brown M (2008) Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma. 49:959-964. (Pubitemid 351942751)
13. Mociková H (2010) Prognostic significance of absolute lymphocyte count and lymphocyte subsets in lymphomas. Prague Med Rep. 111: 5-11.
14. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, et al. (2010) Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 24: 1343-1349.
15. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, et al. (2008) Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol. 81: 448-453.
16. Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, et al. (2010) Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 21: 1486-1491.
17. Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, et al. (2013) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era. Haematologica. 99: 125-130.
18. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, et al. (2012) Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 53: 2159-2165.
19. Cancer Incidence 2010 in the Czech Republic (2010) UZIS, NOR, ISBN 978-80-7472-034-5. Available: www.uzis.cz/system/files/novot2010.pdf. Accessed 2014 May 21.
20. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 328: 1002-1006. (Pubitemid 23095683)
21. Swerdlow SH (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer.
22. R Core Team (2013) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available: http://www.R-project.org/. Accessed 2013 July 30.
23. Aoki K, Tabata S, Yonetani N, Matsushita A, Ishikawa T (2013) The Prognostic Impact of Absolute Lymphocyte and Monocyte Counts at Diagnosis of DiffuseLarge B-Cell Lymphoma in the Rituximab Era. Acta Haematol. 130:242-246.
24. Li ZM, Huang JJ, Xia Y, Sun J, Huang Y, et al. (2012) Blood Lymphocyte-to-Monocyte Ratio Identifies High-Risk Patients in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. PLoS ONE 7(7): e41658. doi:10.1371/journal. pone.0041658.
25. Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. British Journal of Cancer 105: 1684-1692.
26. Pfreundschuh M, Kuhnt E, Trümper L, Österborg A, Trneny M, et al. (2011) MabThera International Trial(MInT) Group. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12: 1013-1022.